Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holger Fuchs

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 6, 2017
Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit StudiesHolger Fuchs, Frederik Igney
Neurochemistry International|September 1, 2004
Changes in extracellular dopamine in the rat globus pallidus induced by typical and atypical antipsychotic drugsHolger Fuchs, Wolfgang Hauber
Neuroscience Letters|May 17, 2003
Reverse microdialysis of ionotropic glutamate receptor agonists in the rat globus pallidus increased extracellular dopamineHolger Fuchs, Wolfgang Hauber
Experimental Brain Research|September 26, 2003
Dopaminergic innervation of the rat globus pallidus characterized by microdialysis and immunohistochemistryHolger Fuchs, Wolfgang Hauber
Neurochemistry International|August 27, 2005
Effects of physiological and pharmacological stimuli on dopamine release in the rat globus pallidusHolger Fuchs, Jens Nagel, Wolfgang Hauber
Biopharmaceutics & Drug Disposition|June 30, 2009
Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in ratsHolger Fuchs, Rudolf Binder, Andreas Greischel
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 27, 2011
Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated effluxHolger Fuchs, Frank Runge, Heinz-Dieter Held
Experimental Eye Research|February 11, 2021
Ocular and systemic pharmacokinetics of BI-X, a nanobody targeting VEGF and Ang-2, after intravitreal dosing in cynomolgus monkeys - Evidence for half-life extension by albuminHolger Fuchs, Lin-Zhi Chen, Sarah Low, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 24, 2014
Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout ratsHolger Fuchs, Wataru Kishimoto, Dietmar Gansser, et al.
The Journal of Pharmacy and Pharmacology|January 8, 2009
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humansHolger Fuchs, Jean-Paul Tillement, Saik Urien, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|January 6, 2017
Binding to Ocular Albumin as a Half-Life Extension Principle for Intravitreally Injected Drugs: Evidence from Mechanistic Rat and Rabbit StudiesHolger Fuchs, Frederik Igney
Neurochemistry International|September 1, 2004
Changes in extracellular dopamine in the rat globus pallidus induced by typical and atypical antipsychotic drugsHolger Fuchs, Wolfgang Hauber
Neuroscience Letters|May 17, 2003
Reverse microdialysis of ionotropic glutamate receptor agonists in the rat globus pallidus increased extracellular dopamineHolger Fuchs, Wolfgang Hauber
Experimental Brain Research|September 26, 2003
Dopaminergic innervation of the rat globus pallidus characterized by microdialysis and immunohistochemistryHolger Fuchs, Wolfgang Hauber
Neurochemistry International|August 27, 2005
Effects of physiological and pharmacological stimuli on dopamine release in the rat globus pallidusHolger Fuchs, Jens Nagel, Wolfgang Hauber
Biopharmaceutics & Drug Disposition|June 30, 2009
Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in ratsHolger Fuchs, Rudolf Binder, Andreas Greischel
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 27, 2011
Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated effluxHolger Fuchs, Frank Runge, Heinz-Dieter Held
Experimental Eye Research|February 11, 2021
Ocular and systemic pharmacokinetics of BI-X, a nanobody targeting VEGF and Ang-2, after intravitreal dosing in cynomolgus monkeys - Evidence for half-life extension by albuminHolger Fuchs, Lin-Zhi Chen, Sarah Low, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 24, 2014
Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout ratsHolger Fuchs, Wataru Kishimoto, Dietmar Gansser, et al.
The Journal of Pharmacy and Pharmacology|January 8, 2009
Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humansHolger Fuchs, Jean-Paul Tillement, Saik Urien, et al.
Pageof 3